KPH2f

Cat. No.: HY-144305

CAS No.: 2760615-09-4

Molecular Formula: $C_{24}H_{16}N_3NaO_2S$

Molecular Weight: 433.46

Target: URAT1; GLUT

Pathway: Membrane Transporter/Ion Channel

Storage: 4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 16.67 mg/mL (38.46 mM; ultrasonic and warming and heat to 80°C)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.3070 mL	11.5351 mL	23.0702 mL
	5 mM	0.4614 mL	2.3070 mL	4.6140 mL
	10 mM	0.2307 mL	1.1535 mL	2.3070 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: 1.67 mg/mL (3.85 mM); Clear solution; Need ultrasonic
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: 1.67 mg/mL (3.85 mM); Clear solution; Need ultrasonic
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: 1.67 mg/mL (3.85 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

KPH2f is a safe, orally active, and effective dual URAT1/GLUT9 inhibitor with IC_{50}s of 0.24 μM and 9.37 μM for URAT1 and GLUT9, respectively. KPH2f shows little effects on OAT1 and ABCG2 (IC_{50}=32.14 and 26.74 μM)[1].

REFERENCES

[1]. Zhao Z, et al. Discovery of novel verinurad analogs as dual inhibitors of URAT1 and GLUT9 with improved Druggability for the treatment of hyperuricemia. Eur J Med Chem. 2022;229:114092.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA